An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

Just as crop-devouring insects evolve to resist pesticides, cancer cells can increase their lethality by developing ...

Researchers explore how established agricultural pest management strategies could be adapted to address cancer therapy. The pioneering method opens new possibilities for controlling drug resistance ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

In 1937, President Franklin Roosevelt signed the National Cancer Act, launching a nationwide effort to combat the disease.

Instead of repressing tumor-suppressor genes, this form of EZH2 drives rapid protein production and activates growth factors like TGF-β, fostering an environment around the tumor that promotes cancer ...

The results could potentially lead to new therapies for patients with limited options and add to the significant progress the teams have made in understanding how advanced prostate cancer develops ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

“This study reveals a critical mechanism behind treatment resistance in prostate cancer, suggesting new therapeutic approaches,” said Dr. Diaz-Meco. “By understanding EZH2’s role in this ...